Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Marchetti, Antonio ^a   Del Grammastro, Maela ^a   Felicioni, Lara ^a   Malatesta, Sara ^a   Filice, Giampaolo ^a   Centi, Irene ^b   De Pas, Tommaso ^c   Santoro, Armando ^d   Chella, Antonio ^e   Brandes, Alba Ariela ^f   Venturino, Paola ^g   Cuccurullo, Franco ^a   Crinò, Lucio ^h   Buttitta, Fiamma ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Oncological and Cardiovascular Molecular Medicine Unit Center of Excellence on Aging University Foundation ^*  (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f BELLARIA HOSPITAL   (Italy)

^g ROCHE MILANO RICERCHE   (Italy)

^h SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADVANCED CANCER; ANALYTICAL EQUIPMENT; ARTICLE; BIOPSY TECHNIQUE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CELL NUCLEUS; CELL SHAPE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PROCEDURES; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROSPECTIVE STUDY; REAL TIME LIQUID BIOPSY; SENSITIVITY AND SPECIFICITY; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; METABOLISM; MOLECULAR GENETICS; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; EXONS; GENE EXPRESSION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84923014763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103883     Document Type: Article

References (33)

1. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, et al. (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18: 5701-5710.
2. Lianidou ES, Markou A (2011) Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem 57: 1242-1255.
3. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221.
4. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309.
5. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29: 1556-1563.
6. Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, et al. (2011) Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 17: 827-835.
7. Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, et al. (2012) Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol 7: 512-519.
8. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, et al. (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12: 4218-4224.
9. Rink M, Chun FK, Dahlem R, Soave A, Minner S, et al. (2012) Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 61: 810-817.
10. Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, et al. (2011) Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/ inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 128: 155-163.
11. Mayo C, Bertran-Alamillo J, Molina-Vila MÁ, Giménez- Capitán A, Costa C, et al. (2012) Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics 13: 789-802.
12. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
13. Han HS, Eom DW, Kim JH, Kim KH, Shin HM, et al. (2011) EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 12: 380-386.
14. Chang YL, Wu CT, Shih JY, Lee YC (2011) Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol 18: 543-550.
15. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, et al. (2010) Molecular biomarker analyses using circulating tumor cells. PLoS One 5: e12517.
16. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, et al. (2009) Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 4: 809-815.
17. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, et al. (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 20: 696-702.
18. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME (2010) Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 56: 1492-1495.
19. Riethdorf S, Pantel K (2010) Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Annals of the New York Academy of Sciences 1210: 66-77.
20. Miller MC, Doyle GV, Terstappen LW (2010) Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010: 617421.
21. Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, et al. (2012) Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One 7: e42164.
22. Mardis ER (2008) Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 9: 387-402.
23. Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, et al. (2013) Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res 19: 691-698.
24. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, et al. (2012) Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18: 2391-2401.
25. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, et al. (2007) Isolation of rare circulating tumor cells in cancer patients by microchip technology. Nature 450: 1235-1239.
26. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377.
27. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, et al. (2010) Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2: 25ra23.
28. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, et al. (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107: 18392-18397.
29. Boe Sorensen, Lin Wu, Wei Wen, Julie Tsai, Britta Weber, et al. (2013) Monitoring of EGFR TKI sensitizing and resistance mutations in plasma DNA of advanced adenocarcinoma of NSCLC during erlotinib treatment. 15th World Conference of Lung Cancer. Abstract MO21.07
30. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, et al. (2009) Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 69: 8341-8348.
31. Lianidou ES, Mavroudis D, Georgoulias V (2013) Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer 108: 2426-2432.
32. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, et al. (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8: 45-51.
33. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, et al. (2011) Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17: 3812-3821.